Header Logo

Connection

RAJENDER APARASU to Adolescent

Back to Details
This is a "connection" page, showing publications RAJENDER APARASU has written about Adolescent.
RAJENDER APARASU
Connection Strength
1.280
Adolescent
  1. Marginal health care expenditures for melanoma care in the United States. J Manag Care Spec Pharm. 2024 Dec; 30(12):1364-1374.
    View in: PubMed
    Score: 0.066
  2. Comparative effectiveness of high-efficacy and moderate efficacy disease-modifying agents in reducing the annualized relapse rates among multiple sclerosis patients in the United States. Prev Med. 2025 Jan; 190:108180.
    View in: PubMed
    Score: 0.066
  3. Infection Risk Associated with High-Efficacy Disease-Modifying Agents in Multiple Sclerosis: A Retrospective Cohort Study. Clin Pharmacol Ther. 2025 Feb; 117(2):561-569.
    View in: PubMed
    Score: 0.066
  4. Factors associated with the initiation of high-efficacy disease-modifying agents over moderate-efficacy disease-modifying agents in multiple sclerosis. Mult Scler Relat Disord. 2024 Nov; 91:105896.
    View in: PubMed
    Score: 0.066
  5. Association of oral disease-modifying agents and their adherence trajectories with annual relapses in multiple sclerosis. Mult Scler Relat Disord. 2024 May; 85:105539.
    View in: PubMed
    Score: 0.063
  6. Real-world Comparative Effectiveness of Methotrexate-based Combinations for Rheumatoid Arthritis: A Retrospective Cohort Study. Clin Ther. 2023 09; 45(9):e177-e186.
    View in: PubMed
    Score: 0.061
  7. Risk of incident cardiovascular events with disease-modifying anti-rheumatic drugs among adults with rheumatoid arthritis: a nested case-control study. Clin Rheumatol. 2024 Jan; 43(1):103-116.
    View in: PubMed
    Score: 0.061
  8. FACTORS ASSOCIATED WITH SWITCHING FROM INJECTABLE TO ORAL DISEASE MODIFYING AGENTS AMONG PATIENTS WITH MULTIPLE SCLEROSIS. Mult Scler Relat Disord. 2022 Apr; 60:103703.
    View in: PubMed
    Score: 0.055
  9. Factors Associated with Prescribing Oral Disease Modifying Agents in Multiple Sclerosis: a Real-world Analysis of Electronic Medical Records. Mult Scler Relat Disord. 2020 Oct; 45:102334.
    View in: PubMed
    Score: 0.049
  10. Marginal Health Care Expenditure Burden Among U.S. Civilian Noninstitutionalized Individuals with Multiple Sclerosis: 2010-2015. J Manag Care Spec Pharm. 2020 Jun; 26(6):741-749.
    View in: PubMed
    Score: 0.049
  11. Documentation of asthma control and severity in pediatrics: analysis of national office-based visits. J Asthma. 2020 02; 57(2):205-216.
    View in: PubMed
    Score: 0.044
  12. Asthma Medication Prescribing Practices in Pediatric Office Visits. Clin Pediatr (Phila). 2019 04; 58(4):395-405.
    View in: PubMed
    Score: 0.044
  13. The Impact of Pharmacotherapy on Substance Use in Adolescents With Attention-Deficit/Hyperactivity Disorder: Variations Across Subtypes. Subst Use Misuse. 2017 08 24; 52(10):1266-1274.
    View in: PubMed
    Score: 0.039
  14. Cardiovascular Safety of Concomitant Use of Atypical Antipsychotics and Long-Acting Stimulants in Children and Adolescents With ADHD. J Atten Disord. 2019 01; 23(2):163-172.
    View in: PubMed
    Score: 0.035
  15. Predictors of concomitant use of antipsychotics and stimulants and its impact on stimulant persistence in pediatric attention deficit hyperactivity disorder. J Manag Care Spec Pharm. 2015 Jun; 21(6):486-98.
    View in: PubMed
    Score: 0.034
  16. Concurrent use of stimulants and second-generation antipsychotics among children with ADHD enrolled in Medicaid. Psychiatr Serv. 2015 Apr 01; 66(4):404-10.
    View in: PubMed
    Score: 0.033
  17. Persistence of stimulants in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2012 Apr; 22(2):139-48.
    View in: PubMed
    Score: 0.027
  18. Prevalence and predictors of human papillomavirus vaccination in adolescent girls. J Am Pharm Assoc (2003). 2012 Jan-Feb; 52(1):52-8.
    View in: PubMed
    Score: 0.027
  19. The definition and prevalence of pediatric psychotropic polypharmacy. Psychiatr Serv. 2011 Dec; 62(12):1450-5.
    View in: PubMed
    Score: 0.027
  20. Extent of functional impairment in children and adolescents with depression. Curr Med Res Opin. 2010 Sep; 26(9):2057-64.
    View in: PubMed
    Score: 0.025
  21. Unmet prescription medication need in U.S. children. J Am Pharm Assoc (2003). 2009 Nov-Dec; 49(6):769-76.
    View in: PubMed
    Score: 0.023
  22. Health care consequences of black-box warnings for antidepressants in the United States and Canada. Res Social Adm Pharm. 2010 Mar; 6(1):78-84.
    View in: PubMed
    Score: 0.023
  23. Pharmacotherapy with atomoxetine for US children and adolescents. Ann Clin Psychiatry. 2007 Jul-Sep; 19(3):175-80.
    View in: PubMed
    Score: 0.020
  24. Patterns and determinants of antipsychotic prescribing in children and adolescents, 2003-2004. Curr Med Res Opin. 2007 Jan; 23(1):49-56.
    View in: PubMed
    Score: 0.019
  25. Metabolic Monitoring for Children and Adolescents Prescribed Second-Generation Antipsychotics: A Qualitative Study with Child Psychiatrists. J Child Adolesc Psychopharmacol. 2024 10; 34(8):359-365.
    View in: PubMed
    Score: 0.016
  26. Adherence to Recommended Metabolic Monitoring of Children and Adolescents Taking Second-Generation Antipsychotics. Psychiatr Serv. 2024 Apr 01; 75(4):342-348.
    View in: PubMed
    Score: 0.015
  27. Trends in Repeat Opioid Analgesic Prescription Utilization for Acute Pain in Children: 2013-2018. Acad Pediatr. 2024 07; 24(5):776-782.
    View in: PubMed
    Score: 0.015
  28. Association Between Abnormal Metabolic Parameters and Receiving Subsequent Interventions in Children and Adolescents Initiating Second-Generation Antipsychotics. J Child Adolesc Psychopharmacol. 2023 09; 33(7):269-278.
    View in: PubMed
    Score: 0.015
  29. Impact of the AACAP practice parameters on the metabolic adverse event monitoring for second-generation antipsychotics (SGAs) in children and adolescents. J Psychiatr Res. 2023 09; 165:170-173.
    View in: PubMed
    Score: 0.015
  30. Impact of geographic access to primary care providers on pediatric behavioral health screening. Prev Med. 2021 12; 153:106856.
    View in: PubMed
    Score: 0.013
  31. Autonomous ambulatory care by nurse practitioners and physician assistants in office-based settings. J Allied Health. 2001; 30(3):153-9.
    View in: PubMed
    Score: 0.013
  32. Utilization of ambulatory care services caused by adverse effects of medications in the United States. Manag Care Interface. 2000 Apr; 13(4):70-5.
    View in: PubMed
    Score: 0.012
  33. Racial/ethnic differences in treatment quality among youth with primary care provider-initiated versus mental health specialist-initiated care for major depressive disorders. Child Adolesc Ment Health. 2020 02; 25(1):28-35.
    View in: PubMed
    Score: 0.012
  34. Opioid-induced emesis among hospitalized nonsurgical patients: effect on pain and quality of life. J Pain Symptom Manage. 1999 Oct; 18(4):280-8.
    View in: PubMed
    Score: 0.012
  35. Reversibility of psychotropic medication induced weight gain among children and adolescents with bipolar disorders. Psychiatry Res. 2019 06; 276:151-159.
    View in: PubMed
    Score: 0.011
  36. The association between geographic access to providers and the treatment quality of pediatric depression. J Affect Disord. 2019 06 15; 253:162-170.
    View in: PubMed
    Score: 0.011
  37. Physician Care Coordination and the Use of Psychotropic Polypharmacy in the Management of Pediatric Mental Disorders. J Manag Care Spec Pharm. 2019 Jan; 25(1):29-38.
    View in: PubMed
    Score: 0.011
  38. Risk factors of psychotropic polypharmacy in the treatment of children and adolescents with psychiatric disorders. Res Social Adm Pharm. 2019 04; 15(4):395-403.
    View in: PubMed
    Score: 0.011
  39. Drug-related-injury visits to hospital emergency departments. Am J Health Syst Pharm. 1998 Jun 01; 55(11):1158-61.
    View in: PubMed
    Score: 0.011
  40. Outcomes associated with Clostridium difficile infection in patients with chronic liver disease. Epidemiol Infect. 2018 07; 146(9):1101-1105.
    View in: PubMed
    Score: 0.011
  41. Racial/ethnic differences in the treatment of adolescent major depressive disorders (MDD) across healthcare providers participating in the medicaid program. J Affect Disord. 2018 08 01; 235:155-161.
    View in: PubMed
    Score: 0.010
  42. Effect of Psychopharmacotherapy on Body Mass Index Among Children and Adolescents with Bipolar Disorders. J Child Adolesc Psychopharmacol. 2017 May; 27(4):349-358.
    View in: PubMed
    Score: 0.010
  43. Care Provision and Prescribing Practices of Physicians Treating Children and Adolescents With ADHD. Psychiatr Serv. 2017 Jul 01; 68(7):681-688.
    View in: PubMed
    Score: 0.010
  44. Risk of manic switch associated with antidepressant therapy in pediatric bipolar depression. J Child Adolesc Psychopharmacol. 2014 Dec; 24(10):551-61.
    View in: PubMed
    Score: 0.008
  45. Comparative effectiveness of monotherapy with mood stabilizers versus second generation (atypical) antipsychotics for the treatment of bipolar disorder in children and adolescents. Pharmacoepidemiol Drug Saf. 2014 Mar; 23(3):299-308.
    View in: PubMed
    Score: 0.008
  46. The utilization of psychopharmacological treatment and medication adherence among Medicaid enrolled children and adolescents with bipolar depression. J Affect Disord. 2013 Sep 05; 150(2):424-9.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.